Based on the information provided, there are no specific clinical trials listed that used Polivy (generic name: polatuzumab vedotin) data. However, the first source, a drug patent watch website, does confirm that Polivy is a medication using polatuzumab vedotin as its active ingredient.

The European Medicines Agency (EMA) website, the second source, provides information on the clinical data publication for medicines authorized in the European Union. According to this source, the EMA conducts a scientific evaluation of medicines and makes a recommendation on whether a medicine should be authorized for use in the EU. The clinical trial data used in these evaluations are made publicly available after a medicine has been authorized. As Polivy was approved for use in the EU in 2019, any clinical trials using Polivy data should be available on the EMA website. However, a specific search for these trials is not possible with the information provided.

The third source, the NIH Data Management, Sharing, and Citation Policy, does not provide any information relevant to the question.

In conclusion, while there is no specific information available regarding the clinical trials that used Polivy data, the EMA website is a resource for such information. You can visit the EMA website and search for the clinical trial data of Polivy using the product name or active ingredient.

Sources:

1. <https://www.drugpatentwatch.com/p/biologics/tradename/POLIVY>
2. <https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/clinical-data-publication>
3. <https://oir.nih.gov/sourcebook/intramural-program-oversight/intramural-data-sharing/2023-nih-data-management-sharing-policy>